Clinical Outcomes of Non-variceal Upper Gastrointestinal Bleeding and its Relation to Aspirin and Anticoagulants

Hend Radwan¹*, Ehab Elsayed¹, Hesham Alshabrawi²

¹Department of Internal Medicine, National Research Center, Cairo, Egypt; ²Department of Internal Medicine, Ahmed Maher Teaching Hospital, Cairo, Egypt

Abstract

BACKGROUND: Non-variceal upper gastrointestinal bleeding (NVUGIB) is a life-threatening emergency that requires an urgent management. Antiplatelet (e.g., aspirin) and anticoagulant drugs are widely chronically used in various cardiac and coronary artery diseases. These drugs increase the risk of NVUGIB as they may cause ulceration of the upper gastrointestinal (GI) mucosa directly or may cause bleeding or rebleeding. The management of NVUGIB is complicated as the risk between GI bleeding episodes and cardiovascular attacks needs to be well managed.

AIM: The aim of this study is to determine the impact of antiplatelets (aspirin) and anticoagulants use on the morbidity, mortality, and clinical outcomes in patients presented with non-variceal GI bleeding.

PATIENTS AND METHODS: A total of 105 patients presented with melena and/or hematemesis and diagnosed by upper GI endoscopy were enrolled in a prospective cohort study. Patients were sub-grouped according to their use of antiplatelets, anticoagulants, or none (controls). Patients were excluded if they had portal hypertension or nonsteroidal anti-inflammatory drugs (NSAIDs) use and divided into five groups: Group I – patients who had not taken antiplatelets and anticoagulants; Group II – patients on clopidogrel and ticlopidine with or without aspirin; Group III – patients on aspirin only; Group IV – patients on clopidogrel and ticlopidine with or without aspirin; and Group V – patients on combined anticoagulants and antplatelet. All patients were subjected to clinical, laboratory (complete blood count, liver function tests, renal function tests, prothrombin time, and partial thromboplastin time), and endoscopic investigations. Clinical details were reported including admission, blood transfusion, rebleeding, and mortality.

RESULTS: Full medical history revealed that 43 patients were diabetic, 45 patients were cardiac, and 67 patients were hypertensive. Regarding the history of analgesic drug intake, 38 patients used NSAIDs and 29 of them used non-selective NSAIDs and 8 patients used selective NSAIDs. There were non-significant differences among the studied groups with NVUGIB regarding sex, hematemesis only presentation, melena only presentation, liver function tests, and endoscopic findings. On the other hand, there were statistically significant differences between the studied groups with NVUGIB regarding increasing age. NSAIDs use whatever selective or non-selective, decrease level of HB, WBCs, serum albumin, bleeding profile, kidney function tests, clinical presentation in the form of hematemesis and melena, need for blood transfusion, history of associated diseases, especially being cardiac patients, rebleeding after 6 and 12 months, and mortality.

CONCLUSION: Aspirin intake may be associated with less favorable clinical outcomes in patients with NVUGIB, while combined anticoagulants and antiplatelets seem to be associated with the worse outcomes.

Introduction

Non-variceal upper gastrointestinal bleeding (NVUGIB) is a critical clinical condition that requires an urgent management [1, 2]. It remains a clinically important due to the increase in the proportion of elderly population, use of nonsteroidal anti-inflammatory drugs (NSAIDs) [3].

The incidence of upper gastrointestinal bleeding (UGIB) is 2-fold greater in males than in females, in all age groups; however, the death rate is similar in both sexes [4].

The initial laboratory tests include a blood count, international normalized ratio, partial thromboplastin time, electrolytes, creatinine, and blood typing in case transfusion is necessary [5].
**Resuscitation**

The first priority is to correct fluid losses and restore blood pressure. Thus, intravenous (IV) access is a must [7].

**Blood transfusion**

The timing and amount of blood transfusions are valuable. It is accepted that patients with a hemoglobin level of ≤7 g/dL should receive a transfusion, whereas it is rarely indicated in patients with a hemoglobin level of ≥10 g/dL [8].

**Pre-endoscopic care**

Recent consensus suggests that nasogastric lavage is not helpful for diagnosis, prognosis [9], [10]. Pre-endoscopic use of proton-pump inhibitors (PPIs) is highly important [11].

**Endoscopy**

It is the principle diagnostic tool in UGIB and hemostatic therapy. While diagnostic endoscopy in clinically stable patients without relevant comorbidity is safe, complications may occur [9].

There are various endoscopic techniques: injection with epinephrine; clip application; thermocoagulation, argon plasma coagulation or injection with alcohol; fibrin; or thrombin glue [12].

The combination of epinephrine injection with one of the above-mentioned therapies significantly reduces rebleeding, need for surgery, and mortality [13].

Second look endoscopy has to be outweighed with potential risks [8]. On the contrary, another cost-effectiveness study [14] found endoscopy is more effective and less expensive.

The highest risk for rebleeding in patients treated with a combination of endoscopic and PPI therapy is within the first 72 h after the initial bleeding episode [15,16].

**Medical therapy after endoscopy**

IV bolus followed by infusion of high-dose PPI reduces recurrent bleeding, need for repeated endoscopy, surgery, and blood transfusion [17], [18]. However, in patients with lower risk standard, PPI therapy (e.g., oral PPI once daily) is enough [19].

**Other considerations**

Surgery offers a better chance to secure hemostasis [20]. Angiographic embolization should be considered as an alternative to surgery [21].

**Helicobacter pylori**

The successful eradication of an associated *H. pylori* infection lowers the risk of reappearance of an ulcer in the 1st year after hemorrhage to <5% [22].

It is well known that *H. pylori* testing might reveal false-negative results in the setting of an acute bleeding episode [23].

**NSAID use**

In patients with NSAID-associated bleeding ulcers, the need for NSAIDs should be carefully assessed. In patients who must continue on NSAIDs, a cyclooxygenase-2 selective NSAID plus PPI offers the best available upper gastrointestinal (GI) protection [24], [25], [26].

**NVUGIB and antiplatelet and antithrombotic**

Nowadays, many patients receive chronic antiplatelet therapy for various cardiac diseases (Figure 2) [27].

[Table: Causes of non-variceal upper gastrointestinal bleeding]

| Nonvariceal bleeding (%) | Portal hypertensive bleeding (%) |
|--------------------------|---------------------------------|
| Peptic ulcer disease (30-50) | Gastroesophageal varices (>90) |
| Mallory-Weiss tears (15-20) | Hyperensive portal gastropathy (<5) |
| Gastritis or duodenitis (10-15) | Isolated gastric varices (rare) |
| Esophagitis (5-10) | Anteryovenous malformations (5) |
| Ulcers (2) | Others (5) |

Adapted from Ferguson CB, Mitchell RJ. Nonvariceal upper gastrointestinal bleeding: Standard and new treatment. Gastroenterol Clin North Am 2005;34:607-31. GE Gastroenterol

The relative risk for UGIB increases up to 10% in patients treated with these therapies [28], [29], [30]. This complication puts affected patients into an acutely life-threatening situation because the mortality from UGIB ranges from 1% to 13% [31], [32], [33]. Therefore, therapy with ASA or clopidogrel in patients with cardiovascular risk factors should be restarted as soon as possible [8].

Anticoagulant therapy has historically consisted of heparins for the treatment of acute thrombosis and Vitamin K antagonists (VKA) for long-term treatment [34].

VKAs are indicated in patients with atrial fibrillation, thromboembolic venous disease, or a mechanical heart valve, while, recently, the novel oral anticoagulants, such as dabigitran, rivaroxaban, and apixaban, have been used in non-valvular atrial fibrillation and venous thromboembolism [35].

The indications of antiplatelet drugs use are in the management of thrombotic diseases include stroke, acute myocardial infarction, acute coronary syndrome, and angina [36].

Clopidogrel requires cytochrome P450 isoenzyme CYP2C19 to be converted to its active metabolite [37]. PPI and clopidogrel compete for the same cytochrome P450 isoenzyme [38], [39], [40], [41], [42], but other studies did not reveal an increase in cardiovascular events [42], [43].
In the current study, we aim to determine the impact of antiplatelets and anticoagulants on the morbidity, mortality, and clinical outcomes in patients presented with non-variceal GI bleeding.

Patients and Method

This study included 105 patients admitted in Ain Shams University Hospitals and Ahmed Maher Teaching Hospital whom presented with hematemesis and/or melena and diagnosed by upper GI endoscopy and divided into five groups according to the drug intake.

Group I: Patients who had not taken anticoagulants and antiplatelet.

Group II: Patients on anticoagulants (heparin, warfarin, and low-molecular-weight heparin [LMWH] only).

Group III: Patients on aspirin only.

Group IV: Patients on clopidogrel and ticlopidine with or without aspirin.

Group V: Patients on combined anticoagulants and antiplatelet.

Patients were excluded if there were other causes of UGIB (esophageal varices, portal hypertensive gastropathy, and gastric varices if the bleeding source was gastric cancer; if bleeding was associated with endoscopic procedures such as endoscopic mucosal resection, or if bleeding occurred in the lower GI tract).

Methods

A written consent was taken from all participants and oral explanation of the whole procedure, in which they will be involved in. A full history taking including age-associated medical conditions as diabetes mellitus, cardiac, hypertension, gender, history of drug intake (NSAID) and antithrombotic drugs, and history of any inserted cardiac prostheses that might be a causal relationship to the hemorrhage (coronary stents and platelet aggregation inhibitors, cardiac valvular prostheses and anticoagulants, and aortic prostheses with the risk of an aortointestinal fistula). Full examination and full laboratories were done, including complete blood count, liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], serum albumin, and total and direct bilirubin), renal function tests (serum creatinine and blood urea), and prothrombin time and partial thromboplastin time. Upper endoscopy was done by expert (one expert in each hospital to decrease the bias) endoscopists using fiber-optic endoscopy after good sterilization. Initial assessment and resuscitation according to the amount of bleeding (mild-moderate-massive), urgently or within 24–48 h (all patients were intravenously administered PPIs) was performed. Then, follow-up of our studied patients for rebleeding and mortality after 6 and 12 months after discharge from the hospital was done.

Statistical analysis

The collected data were tabulated and statistically analyzed using SPSS software (Statistical Package for the Social Sciences, version 16, SPSS Inc., Chicago, IL, USA). For quantitative data, the range, mean, and standard deviation were calculated. For qualitative data, the comparison between two groups was done by Chi-square test. For comparison between more than two means of data, F value of ANOVA test was calculated. Significance was at p < 0.05 for the results of the tests of significance.

Results

The study included 105 patients who were divided into five groups: Group I: Thirty patients (14 men [46.6%] and 16 women [53.3%]) who had not taken anticoagulants and antiplatelet, their mean age of 44.56 ± 7.63. Group II: Twenty patients on heparin, warfarin, and LMWH only. They were 8 males (40%) and 12 females (60%) with their mean age of 45.72 ± 6.84. Group III: Twenty-five patients on aspirin only who were 12 men (48%) and 13 women (52%) with a mean age of 53.50 ± 5.39. Group IV: Fifteen patients (9 men [60%] and 6 men [40%]) on clopidogrel and ticlopidine with or without aspirin with a mean age of 55.19 ± 6.47. Group V: Fifteen patients 10 male (66.6%) and 5 female (33.3%) who were on combined anticoagulants and antiplatelet with their mean age of 56.46 ± 7.35 (Table 1).

Table 1: Demographic findings of the studied patients

| Group number | I (30) | II (20) | III (25) | IV (15) | V (15) | p value |
|--------------|--------|---------|----------|---------|--------|---------|
| Age (mean±SD)| 44.56±7.63 | 45.72±6.84 | 53.50±5.39 | 55.19±6.47 | 56.46±7.35 | 0.000 |
| Sex | | | | | | |
| Male n (%) | 14 (46.6%) | 8 (40%) | 12 (48%) | 9 (60%) | 10 (66.6%) | 0.519 |
| Female n (%) | 16 (53.3%) | 12 (60%) | 13 (52%) | 6 (40%) | 5 (33.3%) | |

The study revealed that the sex among the studied groups was not statistically significant (p = 0.519). Age of the patients was statistically significant (p = 0.000), as shown in Table 1.

According to the laboratory profile of the studied patient groups, all were statistically significant except for ALT, AST, PLT, and total bilirubin which were statistically insignificant, as shown in Table 2.
Regarding the medical history of the patients, being diabetic or hypertensive or cardiac patient was statistically significant (Table 3).

Our studied patients were presented by NVUGIB, which was either in the form of hematemesis or melena or both together and was the statistically significant symptom (p = 0.011) as shown in Table 4.

Regarding the management of NVUGIB, UGI endoscopy had been performed and the results of the endoscopy are shown in Figure 3 and Table 5, which showed no statistical significance.

According to the management of UGIB, the need for blood transfusion was statistically significant when compared to the studied groups (no need to blood transfusion among the studied groups, p = 0.001 and the need to blood transfusion among the studied groups, p = 0.003), as shown in Table 6 and Figure 4.

Then, we followed up our studied patients after 6 and 12 months after the first attack of NVUGIB and the discharge from the hospital. We followed up the rebleeding episodes and occurrence of mortality while using their medications, we noticed statistically significant values among the studied patients’ groups, as illustrated in Table 7.

**Discussion**

GI bleeding is a serious problem, especially in the elderly and/or multimorbid patients. On the one hand, any anticoagulant and antiplatelet treatment should be discontinued to help stopping the acute bleeding. On the other hand, discontinuing this type of therapy can significantly increase the risk for cardiovascular or cerebrovascular complications due to the underlying disease [44].
Monotherapy with antiplatelet agents or anticoagulants is associated with an increasing risk of UGIB [45]. Therefore, these medications in patients with UGIB should be discontinued for days, even weeks, and during and after bleeding episode [46].

Table 6: Need for blood transfusion in the management of NVUGIB

| Group number | I (30) | II (20) | III (25) | IV (15) | V (15) | p value | p value |
|--------------|--------|---------|----------|---------|--------|---------|---------|
| No need      | 27     | 13      | 6        | 2       | 1      | 0.001   | 46.835  |
| %            | 90     | 65      | 24       | 13.33   | 6.66   | 15.906  | 0.003   |
| Need         | 3      | 7       | 19       | 13      | 14     |         |         |
| %            | 10     | 35      | 76       | 86.66   | 93.33  |         |         |

Although the continuation of low-dose aspirin will increase the risk of rebleeding, it has been reported to be able to reduce all causes of mortality rate in a small sample of patients [47].

Table 7: Rebleeding and mortality after 6 months and 12 months

| Group        | I (30) | II (20) | III (25) | IV (15) | V (15) | p value |
|--------------|--------|---------|----------|---------|--------|---------|
| Rebleeding   | 1      | 3       | 4        | 5       | 5      | 0.046   |
| Mortality    | 29     | 17      | 21       | 10      | 10     |         |
| Rebleeding   | 0      | 0       | 1        | 3       | 3      | 0.032   |
| Mortality    | 30     | 19      | 25       | 14      | 12     |         |
| Rebleeding   | 1      | 3       | 2        | 4       | 6      | 0.046   |
| Mortality    | 29     | 17      | 22       | 11      | 9      |         |
| Rebleeding   | 0      | 0       | 1        | 4       | 4      | 0.032   |
| Mortality    | 30     | 19      | 25       | 14      | 11     |         |

The current evidence on the effects of aspirin or anticoagulants on the clinical outcomes of patients with UGIB is controversial, as Sung et al. [47] have reported that aspirin decreases the mortality of patients while Ortiz et al. [48] have suggested that these drugs have no effects. Similarly, conflicting results on the effects of anticoagulants such as warfarin have been reported [49].

In this study, we aimed to determine the impact of antiplatelets (aspirin) and anticoagulants on the clinical outcomes of 105 patients (53 males and 52 females) aged 36–62 years. Forty-three were diabetic patients, 45 patients were cardiac, and 67 patients were hypertensive; 38 patients used NSAIDS and 29 of them used non-selective NSAIDS and 8 patients used selective NSAIDS who were hospitalized due to NVUGIB and followed up after 6 and 12 months for rebleeding attacks and mortality outcomes.

Statistically significant differences were found among the studied patients regarding age, history of associated disease (especially, cardiac), use of analgesics, clinical presentation of NVUGIB (both hematemesis and melena presenting together), HB, WBCs, bleeding profile, kidney function, serum albumin, need for blood transfusion, rebleeding after 6 and 12 months, and mortality, these results are in conformity with Hearshaw et al. [50] and Modaber et al. [51].

Aging and comorbidities are known predictors of mortality and adverse clinical outcomes [46]. The mortality rate in elderly patients with NVUGIB is increased and the reason is unclear, it may be due to that elderly patients are more prone to have complex comorbidities and be more susceptible to physiological changes associated with acute bleeding episodes than younger patients. Therefore, more careful follow-up with intensive monitoring is needed in this population group following bleeding events.

In our study, we noticed that the patient group on aspirin only had a less mortality and rebleeding events were lower than in other patient groups. Similar protective effects of aspirin against UGIB-related deaths, besides, its cardiovascular benefits had been reported by Sung et al. [47] Webbeh et al. [52], and Souk et al. [53] and also in a study that included both peptic and non-peptic ulcer patients [49].

On the contrary, Ahsberg et al. [54] have reported non-statistically significant association between aspirin use and mortality although those taking NSAIDs were included. In addition, recently, Luo et al. [55] found that the use of aspirin increases the risk of 1st time NVUGIB in general population after adjusting for age, gender, H. pylori infection, underlying comorbidities, and concomitant use of certain medications. Moreover, Taha et al. [56] noticed that a low-dose aspirin intake is associated with longer hospital stays and increased requirements of blood transfusion, but the study included those with variceal bleeding. However, Taha et al. [57] stated that in NVUGIB, the antiplatelet and anticoagulant activities are associated with older age and greater need for admission, transfusion, and rebleeding. The outcomes were more in users of anticoagulants even after adjustment for age, sex, and endoscopy, but with an insignificant effect on mortality.

Aspirin use was a predictor for short length of hospital stay in our study, which is consistent with a better overall outcome for those patients. This is different from what has been reported, which might be due to varied study designs [47] or the patients included in the study (both peptic ulcer disease [PUD] and non-PUD-related UGIB) [48].

On the other hand, Lanas et al. [49] observed that anticoagulants use to increase the requirements for blood transfusion and are associated with a longer hospital stay. Marmo et al. [4] showed that heparin, but not warfarin, increases mortality risk.

In our studied patients groups, we noticed that the most common cause of NVUGIB by endoscopy was gastritis followed by esophageal erosions then GU, but all with no statistically significant difference. This was not in agreement with Telaku et al. [58] who stated that the most common cause of NVUGIB was peptic ulcer.

Rebleeding is a predictor of mortality [50]. Rubin et al. [59] have suggested that the risk of rebleeding is not affected by antithrombotic. However, aspirin continuation seems to be associated with its increased risk of rebleeding.
Non-bleeding related causes accounted for most deaths, which is in accordance with Wong et al. [60] who concluded that the number of patients who died of acute renal failure in their study was high enough to be considered as an independent risk factor of death [60], while we considered as a part of multiorgan failure.

Malignancies were also responsible for the non-bleeding-related deaths which were observed during follow-up periods. That was in agreement with the results of Marmo et al. [61], while cardiovascular causes were high [61].

Conclusion

Our study suggested that aspirin intake may be associated with less favorable clinical outcomes in UGIB, while combined anticoagulants and antiplatelet seem to be associated with worse clinical outcomes.

Recommendations

• Study a larger scale of patients in many centers to decrease the bias.
• Patients on low-dose ASA should be tested for H. pylori.
• A discussion and ultimately a consensus among gastroenterologists and cardiologists with respect to the benefit-risk ratios are desirable.
• Adding a questionnaire to assess the quality of life before and after being admitted and endoscopically and medically managed during the episode of NVUGIB.

Limitations

Our study has some limitations and pitfalls:
• The small number of studied patients as we selected the patients with an emergency presentation (hematemesis and/or melena) and need to follow them up for a long time, which can be avoided if the study was retrospective.
• H. pylori analysis for the studied patients with NVUGIB which was not performed.
• Lack of endoscopic scoring system.

Acknowledgment

We would like to thank Dr. Hany Aly, Assistant Professor of Gastroenterology at Ain Shams University Hospitals, for his effort in performing UGI endoscopy to our studied patients.

References

1. Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol. 2009;9:25. https://doi.org/10.1186/1471-230x-9-25 PMid:19379513
2. Loperfido S, Baldou V, Piovesana E, Bellina L, Rossi K, Groppo M, et al. Changing trends in acute upper-GI bleeding: A population-based study. Gastrointest Endosc. 2009;70(2):212-24. https://doi.org/10.1016/j.gie.2008.10.051 PMid:19409558
3. Kim SY, Hyun JJ, Jung SW, Lee SW. Management of non-variceal upper gastrointestinal bleeding. Clin Endosc. 2012;45(3):220-3. https://doi.org/10.5946/ce.2012.45.3.220 PMid:22977806
4. Marmo R, Koch M, Cipolletta L, Capurso L, Grossi E, Cestari R, et al. Predicting mortality in non-variceal upper gastrointestinal bleeders: Validation of the Italian PNED score and prospective comparison with the rockall score. Am J Gastroenterol. 2010;105(6):1284-91. https://doi.org/10.1038/ajg.2009.687 PMid:20051943
5. Biecker E, Heller J, Schmitz V, Lammert F, Sauerbruch T. Diagnosis and management of upper gastrointestinal bleeding. Dtsch Arztebl Int. 2008;105(5):85-94. https://doi.org/10.3238/arztebl.2008.0085 PMid:19633792
6. NICE Clinical Guideline: Acute Upper Gastrointestinal Bleeding: Management; 2015. Available from: http://www.guidance.nice.org.uk/cg. [Last accessed on 2019 May 11].
7. British Society of Gastroenterology Endoscopy Committee, Palmer KR. Non-variceal upper gastrointestinal haemorrhage: Guidelines. Gut. 2002;51(Suppl 4):iv1-6. PMid:12208839
8. Biecker E. Diagnosis and therapy of non-variceal upper gastrointestinal bleeding, World J Gastroint Pharmacol Ther. 2015;6(4):172-82. https://doi.org/10.4292/wjgpt.v6.i4.172 PMid:26558151
9. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101-13. PMid:20083829
10. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345-60. PMid:22310222
11. Sreedharan A, Martin J, Leontiadis GI, Donward S, Howden CW, Forman D, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;7:CD005415. https://doi.org/10.1002/14651858.cd005415.pub2 PMid:20614440
12. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: A systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-62. https://doi.org/10.1001/jamainternalmed.2014.4056
Interactions between clopidogrel and aspirin has a protective effect against adverse outcomes in patients with nonvariceal upper gastrointestinal bleeding. A randomized trial. Ann Intern Med. 2010;152(1):1-9. https://doi.org/10.7326/0003-4819-152-1-201001050-00179
PMid:19949136

48. Ortiz V, Ortuño J, Rodríguez-Soler M, Iborra M, Garrigues V, Ponce J. Outcome of non-variceal acute upper gastrointestinal bleeding in patients with antithrombotic therapy. Digestion. 2009;80(2):89-94. https://doi.org/10.1159/000193495
PMid:19828953

49. Lanasa, Aabakken L, Fonseca J, MunganZA, Papatheodoridis GV, Plesseaux H, et al. Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. Aliment Pharmacol Ther. 2011;33(11):1225-33. https://doi.org/10.1111/j.1365-2036.2011.04651.x
PMid:21480935

50. Hearnsahw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: Patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60(10):1327-35. https://doi.org/10.1136/gut.2010.228437
PMid:21490373

51. Modaber AA, Hammad A, Aliyev V. Effects of aspirin and anticoagulants on morbidity and mortality in patients with non-variceal upper gastrointestinal bleeding. Int J Hepatol Gastroenterol. 2017;3(3):71-8.

52. Wehbeh A, Tamim HM, Abu Daya H, Abou Mrad R, Badreddine RJ, Eloubeidi MA, et al. Aspirin has a protective effect against adverse outcomes in patients with nonvariceal upper gastrointestinal bleeding. Dig Dis Sci. 2015;60(7):2077-87. https://doi.org/10.1007/s10620-015-3604-1
PMid:25732717

53. Souk KM, Tamim HM, Abu Daya HA, Rockey DC, Barada KA. Aspirin use for primary prophylaxis: Adverse outcomes in non-variceal upper gastrointestinal bleeding. World J Gastrointest Surg. 2016;8(7):501-7. https://doi.org/10.4240/wjgs.v8.i7.501
PMid:27462392

54. Åhsberg K, Höglund P, Staël von Holstein C. Mortality from peptic ulcer bleeding: The impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther. 2010;32(6):801-10. https://doi.org/10.1111/j.1365-2036.2010.04399.x
PMid:20653635

55. Luo PJ, Lin XH, Lin CC, Luo JC, Hu HY, Ting PH, et al. Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study. J Formos Med Assoc. 2019;118(5):939-44. https://doi.org/10.1016/j.jfma.2018.10.007
PMid:30366771

56. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Clinical outcome in upper gastrointestinal bleeding complicating low-dose aspirin and antithrombotic drugs. Aliment Pharmacol Ther. 2006;24(4):633-6. https://doi.org/10.1111/j.1365-2036.2006.03017.x
PMid:16907895

57. Taha A, McCloshney C, Craigen T CC, Angerson W. Antiplaletet versus anticoagulant effects in non-variceal upper gastrointestinal bleeding. Gut. 2019;68(Suppl 2):A1-269. https://doi.org/10.1136/gutjnl-2019-319208
PMid:31400941

58. Telaku S, Kraja B, Qirjako G, Prifti S, Fejza H. Clinical outcomes of nonvariceal upper gastrointestinal bleeding in Kosovo. Turk J Gastroenterol. 2014;25(Suppl 1):110-5. https://doi.org/10.5152/...
59. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: Endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc. 2003;58(3):369-73. https://doi.org/10.1016/s0016-5107(03)00010-5
PMid:14528210

60. Wong GL, Wong VW, Chan Y, Ching JY, Au K, Hui AJ, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology. 2009;137(2):525-31. https://doi.org/10.1053/j.gastro.2009.05.006
PMid:19445937

61. Marmo R, Koch M, Cipolletta L, Capurso L, Pera A, Bianco MA, et al. Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: A multicenter study. Am J Gastroenterol. 2008;103(7):1639-47.
PMid:18564127